TSLA
Tesla
-- 230.330 NVDA
NVIDIA
-- 108.715 PLTR
Palantir
-- 78.000 AAPL
Apple
-- 220.830 AMD
Advanced Micro Devices
-- 96.755 
NEWS
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
Precision BioSciences (Nasdaq: DTIL) presented preclinical data at the ESGCT 31st Annual Congress showcasing their ARCUS platform'scapability for high-efficiency gene editing through homology-directed repair (HDR). The research demonstrated gene insertion rates exceeding 85% in T cells and 39% in non-dividing primary human hepatocytes.
The ARCUS platform showed versatility in DNA editing, achieving all twelve possible base changes, specific base removal and insertions, and whole gene replacements. This capability extends beyond current limitations of base editors and prime editors, potentially offering broader therapeutic applications for diseases requiring function restoration.
The ARCUS platform showed versatility in DNA editing, achieving all twelve possible base changes, specific base removal and insertions, and whole gene replacements. This capability extends beyond current limitations of base editors and prime editors, potentially offering broader therapeutic applications for diseases requiring function restoration.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment